Last updated: February 12, 2026
Overview of the Product
NDC 00074-0124 refers to Liraglutide injection, marketed under the brand name Victoza. Approved by the FDA in 2010, Victoza is primarily used for type 2 diabetes management and weight control. Since its launch, it has become a leading GLP-1 receptor agonist in the diabetes therapeutic market.
Market Landscape
Market Size and Growth
The global diabetes therapeutics market reached approximately $65 billion in 2022, with biologics like liraglutide accounting for a significant proportion due to patent protections and favorable reimbursement policies. The GLP-1 receptor agonists segment is projected to expand at a compound annual growth rate (CAGR) of 10% from 2022 to 2027, driven by improved clinical outcomes and expanding indications.
Key Market Players
- Novo Nordisk (Victoza)
- Eli Lilly (Trulicity)
- AstraZeneca (Breo)
- Sanofi (Adlyxin/ Lyumjev)
Victoza commands approximately 45% of the global GLP-1 market share, with continued dominance due to its established efficacy and brand recognition.
Regulatory and Patent Trends
Victoza's patent protection extends until 2026, with biosimilar development ongoing in some regions. Patent expirations often influence market prices through increased competition, with biosimilar entry potentially reducing prices by 20–40%.
Pricing Analysis
Current Market Price
In the U.S., the average wholesale acquisition cost (AWAC) of Victoza is approximately $740 per 3 mL pen (containing 18 mg liraglutide). Patients with insurance typically face copayments between $20 and $50, depending on plans.
Historical Price Trends
- Prices have increased marginally (~2-3%) annually since 2015, maintaining consistent margins due to brand strength.
- Biosimilar entrants could reduce prices by up to 30%, based on European biosimilar pricing data.
Reimbursement Environment
Centers for Medicare & Medicaid Services (CMS) covers a substantial share of diabetes medication, and formulary placements influence retail prices. Manufacturers negotiate rebates that can lower net prices by 10–25%.
Future Price Projections
Short-term (1-2 years): 5-10% Increase
- Price stabilization due to market saturation
- Continued insurance negotiations
- Slight inflation driven by raw material costs
Mid-term (3-5 years): 0-15% Decrease
- Potential biosimilar market entry post-2026 patent expiry
- Competitive pressures leading to discounts
- Legislative pressures to contain healthcare costs
Long-term (5+ years): 20-40% Price Reduction
- Biosimilar market penetration
- Patent litigation outcomes
- Possible development of oral or alternative delivery forms reducing reliance on injection formulations
Cost Drivers and Market Risks
- Manufacturing complexities for biologics
- Patent litigation or delays
- Regulatory changes affecting biosimilar approvals
- Adoption rates influenced by clinical guidelines and prescriber preferences
Strategic Recommendations
- Monitor biosimilar pipeline developments for potential price decline opportunities.
- Engage in payer negotiations early to secure favorable formulary positioning.
- Invest in patient education programs to enhance adherence, maximizing lifetime value.
Summary Table: Price Overview
| Period |
Expected Price Movement |
Drivers |
| 0-2 years |
5-10% increase |
Market maturity, stable demand |
| 3-5 years |
0-15% decrease |
Biosimilar competition, patent expirations |
| 5+ years |
20-40% decrease |
Biosimilar market penetration, regulatory changes |
Sources
- IQVIA, "World Preview 2022," IQVIA Institute for Human Data Science.
- Evaluate Pharma, "Global Biosimilar Market Report 2022."
- CMS.gov, "Medicare Part D Drug Pricing."
- FDA, "Biosimilar Guidance and Approvals," 2022.
- MarketWatch, "GLP-1 Receptor Agonists Market Forecast 2022-2027."
Key Takeaways
- Victoza remains a dominant biologic in type 2 diabetes management, with stable prices pre-biosimilar entry.
- Biosimilar development could reduce prices significantly after patent expiration in 2026.
- Short-term pricing growth is limited; long-term outlook suggests potential reductions.
- Market dynamics include regulatory changes, patent litigation, and payer negotiations.
FAQs
1. When is Victoza's patent set to expire?
Patent protection extends until 2026, after which biosimilar competitors are expected to enter the market.
2. What factors could accelerate price reductions?
Biosimilar approval, market approval of generic options, and increased competition can drive prices downward.
3. How does reimbursement affect Victoza's market price?
Insurance negotiations and rebate programs influence the net price paid by payers and patients.
4. Are biosimilars expected to significantly impact Victoza's sales?
Yes, biosimilars are projected to capture 30-50% of the market within 3-5 years of their entry.
5. What is the forecasted price trend for Victoza beyond 2026?
Prices are expected to decrease by 20-40% over the subsequent five years due to biosimilar competition and market pressures.
